Valor202020212022202320242025TTMDespesas comerciais, gerais e administrativas6.12 B6.43 B6.44 B7.4 B8.59 B11.09 B11.56 BPesquisa e desenvolvimento6.09 B7.03 B7.19 B13.11 B14.27 B16.25 B16.04 BLucro operacional17.09 B18.11 B19.72 B24.72 B12.57 B25.99 B31.03 BLucro não operacional, total1.17 B-201.6 M-320.9 M96.7 M-218.6 M-571 M-397 MDespesa com juros, líquida de juros capitalizados359.6 M339.8 M331.6 M485.9 M780.6 M895 M—Receitas não operacionais, líquidas das despesas com juros-434.4 M-592.8 M-638.2 M-356.5 M-193.2 M-571 M-116.6 MReceitas/despesas incomuns1.25 B51.4 M-14.3 M-32.7 M-25.4 M——Lucro antes dos impostos7.23 B6.16 B6.81 B6.55 B12.68 B25.73 B31.13 BParticipação no lucro———————Impostos1.04 B573.8 M561.6 M1.31 B2.09 B5.09 B5.85 BParticipação de minoritários———————Outras receitas/despesas após impostos———————Lucro líquido antes das operações descontinuadas6.19 B5.58 B6.24 B5.24 B10.59 B20.64 B25.28 BOperações descontinuadas00—————Lucro líquido6.19 B5.58 B6.24 B5.24 B10.59 B20.64 B25.28 BAjuste de diluição———————Dividendos de ações preferenciais———————Lucro líquido diluído disponível aos acionistas6.19 B5.58 B6.24 B5.24 B10.59 B20.64 B25.28 BLucro básico por ação6.826.156.935.8211.762328.2Lucro diluído por ação6.796.126.95.811.7122.9528.15Número médio de ações básicas907.63 M906.96 M901.74 M900.18 M900.61 M897.3 M—Ações diluídas912.5 M911.68 M904.62 M903.28 M904.06 M899.3 M—EBITDA18.41 B20.47 B21.24 B26.25 B14.34 B27.99 B33.08 BEBIT17.09 B18.11 B19.72 B24.72 B12.57 B25.99 B31.03 BCusto da receita5.48 B7.31 B6.63 B7.08 B8.42 B11.05 B12.4 BOutros componentes do custo—339.7 M—————Amortização e depreciação (fluxo de caixa)1.32 B1.55 B1.52 B1.53 B1.77 B2 B2.04 B
Eli Lilly and Company Common Stock
Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.
The company is ranked 4th on the list of largest biomedical companies by revenue and is the most valuable pharmaceutical company worldwide. It is ranked 100th on the Fortune 500 and 138th on the Forbes Global 2000. In November 2025, the company reached a $1 trillion market capitalization, the first health-care company in the world to do so.